RE: More than 3 weeks after THE NEWSBladder Cancer - Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) vs. Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer (six-week induction, 10-month maintenance, 24-month follow-up) 17 visits to our Norwood Campus thru end of Maintenance period then standard of care visits during follow-up period. Patient compensation up to $920.
https://theurologygroup.net/clinical-trials/
you will expect that they removed all the email and phone of urologists doing the trial.
Which X day average bioniche will use for stock compensation?